We only have this paper's title and publication details.
Read it at the sourceThis case report details paradoxical skin lesions caused by Xeligekimab in a patient with SAPHO syndrome, suggesting new insights into treatment responses.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: